Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GeoVax Labs, Inc. - Common Stock (NQ:GOVX)

1.020 +0.040 (+4.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GeoVax Labs, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory
GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market
ATLANTA, GA - (NewMediaWire) - July 11, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,... 
Via TheNewswire.com
Topics Regulatory Compliance
Exposures Legal Regulatory
GeoVax Provides First Half 2024 Business Update
Via NewMediaWire
GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax to Present at BIO International Convention 2024
Via TheNewswire.com
Exposures COVID-19
GeoVax to Present Data on GEO-CM04S1, A Next Generation Covid-19 Vaccine, at the World Vaccine Congress
Via NewMediaWire
Exposures COVID-19
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
GeoVax to Present at BIO International Convention 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market
ATLANTA, GA - (NewMediaWire) - May 17, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,... 
Via TheNewswire.com
Topics Regulatory Compliance
Exposures Legal Regulatory
GeoVax Labs, Inc. (NASDAQ: GOVX) Featured in Coverage of the 36th Annual Roth Conference
Via Investor Brand Network
Exposures COVID-19
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines 
Via NewMediaWire
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
From FN Media Group LLC
Via GlobeNewswire
GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory
GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update
Presented data on GEO-CM04S1 at World Vaccine Congress, delineating the unique immune system driven mechanisms that contribute to the broad efficacy of the vaccine candidate 
Via TheNewswire.com
GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
GeoVax to Host Conference Call at 4:30 PM ET 
Via TheNewswire.com
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
Presentation Made During the 24th Annual World Vaccine Congress 
Via TheNewswire.com
Exposures COVID-19
GeoVax to Present at the 36th Annual Roth Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
GeoVax to Host Conference Call at 4:30 PM ET 
Via TheNewswire.com
GeoVax to Present at the 2024 BIO CEO & Investor Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Present at the 2024 BIO CEO &amp; Investor Conference
ATLANTA, GA - (NewMediaWire) - February 19, 2024 - Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today... 
Via TheNewswire.com
GeoVax Announces Multiple Patent Issuances and Allowances
Intellectual Property Assets Strengthened for Cancer Immunotherapy Program 
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants 
Via TheNewswire.com
Exposures COVID-19
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback